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Objective: The current paper reviews the English-language research on exclusion criteria in bipolar disorder
treatment trials and discusses how study samples compare to the general bipolar patient population.
Methods: & Results: Across 8 identiﬁed studies of exclusion criteria and their impact, between 55% and 96% of
people with bipolar disorder would be excluded from treatment research. The number of exclusion criteria varies
across bipolar disorder treatment research, with one study estimate of a median of 7 criteria used across studies.
The criteria that excluded the greatest number of potential participants were comorbid substance use disorder,
suicidal risk, and comorbid medical conditions. Both studies that compared treatment responses among participants who met and did not meet exclusion criteria found no statistically signiﬁcant diﬀerences.
Conclusions: Most potential participants are excluded from outcome research, which creates challenges for recruitment and limits generalizability of study ﬁndings. Common exclusionary practices lead to unrepresentative
samples that limit generalizability and reduce the conﬁdence of clinicians that ﬁndings can be translated to
front-line practice with bipolar disorder patients.

1. Introduction
Bipolar disorder aﬀects 4.4% of the population at some point in
their lifespan [1] and often causes signiﬁcant disruptions to work, social, and family life domains [2] as well as increased suicidal risk [3].
The nature of bipolar disorder and its comorbidities present unique
challenges to treatment researchers, including how to select exclusion
criteria that balance rigor and relevance [4]. More stringent exclusion
criteria can increase the likelihood that a sample will respond to an
evaluated treatment in a homogeneous fashion, which enhances statistical power. Yet, exclusion criteria by deﬁnition widen the gap between research samples and clinical populations, thereby threatening
external validity.
Clinical trials across a range of psychiatric disorders have traditionally attempted to recruit samples of individuals with symptoms
(and related impairment) that emanate exclusively from their primary
diagnosis [5]. This approach to sample selection has raised concerns
regarding the generalizability of research samples to ‘real-world’ community patient populations, most particularly whether “evidencebased” treatments are eﬀective for the severely troubled patients who
tend to be excluded from clinical trials [6]. Some exclusion criteria are
essential to treatment research in order to protect human subjects from

∗

potential harm (e.g., adverse medication interactions). Yet others are
optional and, as such, it is important to consider how the exclusion
criteria may inﬂuence study samples and the implications of potentially
biased samples regarding the generalizability of treatment eﬀects. This
paper reviews the literature on the exclusion criteria that have been
employed in bipolar disorder treatment research, the proportion of
patients excluded, and how exclusion criteria may aﬀect the generalizability of results.
2. Methods
The Cross-disease Review of Exclusion Across Medicine (CREAM)
project is assessing the impact of exclusion criteria in research conducted across a range of medical specialties (e.g., psychiatry, oncology,
rheumatology). A detailed description of the literature review procedure can be found in Humphreys [7]. Literature was primarily identiﬁed by conducting English-language searches in PubMed (Original Date
of Search: July 8, 2013) on the following terms: ‘Eligibility criteria and
generalizability’ (anywhere in paper), ‘exclusion criteria and generalizability’ (anywhere in paper), ‘exclusion criteria’ (in title of paper) and
‘eligibility criteria’ (in title of paper). This generated 326 unique articles, all of which were reviewed by one of the authors, as were relevant
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combined eﬀect of the criteria was to exclude 84% of the participants
who had already been deemed eligible during initial screenings.
Talamo, Baldessarini, and Centorrino [13] reviewed 21 randomized
clinical trials (RCTs) conducted between 1998 and 2008 and identiﬁed
16 exclusion criteria that were widely-used, non-overlapping and which
they had the data to operationalize in medical records of a sample of 67
bipolar inpatients who had received antipsychotic, antimanic, or moodstabilizing medicines and had a diagnosis of mania or a mixed manicdepressive state at the time of discharge. Medical record data were most
commonly excluded based on patients' comorbid substance use (52%)
and a recent suicide attempt (38%). A total of 78% of potential participants' records were excluded by at least one criterion, which is a
conservative estimate of what would be obtained in real-world patient
samples because Talamo et al.’s sample had already been subjected to
some exclusion criteria before being selected for analysis. No statistically signiﬁcant diﬀerences were found between excluded and included
patient records based on several demographic variables (including age,
gender, marital status, employment, education), illness history, current
clinical presentations, or treatment outcome. Regarding treatment received, however, the excluded patients were 24% more likely to receive
2 or more psychotropic agents at discharge, which may have inﬂuenced
their treatment outcome. Data only captured a constrained period of
time (11–13 days), which may have also limited ability to detect differences.
Zarin, Young, and West [14] identiﬁed a set of 3 exclusion criteria
based on 2 published RCTs for valproate and applied them to a sample
of DSM-IV diagnosed bipolar disorder patients (N = 92) drawn from
routine psychiatric practice. All patients in these samples were receiving psychiatric services at the time of data collection. A total of 39%
of the sample would have been excluded for a substance use disorder
diagnosis, 22% for uncontrolled major medical conditions, and 6% for
central nervous system/neuromuscular disorders. Despite only 3 criteria being evaluated, 55% of the sample was excluded under at least
one criterion.
Sachs et al. [15] used a sample of 504 potential participants with a
primary diagnosis of bipolar disorder, manic or mixed episode from
across 47 centers to compare signal detection based on diagnostic criteria as applied by either clinical raters or a computerized assessment.

references within those articles. An updated search was conducted on
August 19, 2016, which yielded an additional 160 unique articles.
Other articles were discovered in a frankly opportunistic fashion. From
this cross-disease pool of literature, evidence related to speciﬁc diseases
were synthesized within focused reviews for a range of diseases, including depression [8], neurological diseases [9], schizophrenia [7],
anxiety disorders [10], and substance use disorders [11]. The present
review focuses on those identiﬁed treatment studies that address overall
and/or speciﬁc criteria exclusion rates for bipolar disorder.
To be considered relevant to the CREAM project, studies had to
analyze data on (1) the prevalence and nature of exclusion criteria,
and/or (2) the impact of exclusion criteria on sample representativeness
or study results. Clinical trials that simply reported their exclusion rate
were not included in this review. Non-participation in research based
on lack of informed consent by eligible participants has quite diﬀerent
implications than exclusion based on factors selected by the researchers. For this reason, lack of informed consent was not considered
as an exclusion criterion in the current review.
3. Results
All included studies (N = 8) evaluated baseline diﬀerences between
included and excluded participants in bipolar disorder treatment studies and two studies also examined outcome diﬀerences. Major ﬁndings
are summarized in Table 1. Potential subjects excluded based on speciﬁc exclusion criteria within each study is presented in Table 2.
Licht and colleagues [12] examined a sample of 164 prospective
participants who were deemed eligible for a research study based on
initial screenings, comparing those who were subsequently included
versus excluded based on various criteria. This sample was drawn from
inpatients with manic symptoms who had been consecutively admitted
to a university hospital. Thirty-nine percent of the sample was excluded
for “methodological reasons” (deﬁned as receiving treatment up to the
time of admission), and another 32% were excluded based on “noncompliance.” Another 4% were excluded for “safety reasons,” which
encompassed having a major medical illness, being pregnant, known
contraindications to the pharmacological treatment of interest, and/or
being in an “extreme manic state requiring other treatment.” The
Table 1
Summary of study ﬁnding.
First author (Year)

Sample size and characteristics

Criteria that excluded the most potential participants (exclusion rate
by criterion)

Exclusion rate

Licht (1997)

164 inpatients with manic symptoms

84%

Talamo (2008)

67 bipolar, acutely manic inpatients

Zarin (2005)

92 patients with acute mania currently receiving psychiatric
services

Sachs (2012)

504 bipolar patients with manic or mixed episode from across 47
centers
785 bipolar depression and 724 bipolar mania community
dwelling patients

1) “Methodological reasons” (39%)
2) “Non-compliance” (32%)
3) “Safety reasons” (4%)
1) Comorbid substance use (52%)
2) Recent suicide attempts (38%)
3) Violent acts (23%)
1) Comorbid substance use (39%)
2) Uncontrolled major medical disorders (22%)
3) Central nervous system/neuromuscular disorder (6%)
Individual criteria not examined.

Hoertel (2013)

Bowden (1995)
Zimmerman (2016)

179 participants and 577 potential participants with acute mania
Not available
(Analysis conducted at study-level; 22 studies)

Filkowski (2015)

163 treatment-refractory bipolar patients referred from
physicians, self, or family

1)
2)
3)
1)
1)
2)
3)
4)
5)
6)
1)
2)
3)

Comorbid substance use (36%, 36%)
Suicide risk (24%, 21%)
Comorbid medical condition (20%, 19%)
Failure to meet diagnostic criteria (32%)
Depressive symptom severity
Suicidal ideation
Alcohol/drug use disorder
Comorbid psychiatric disorder
Duration of current depression episode
Current manic symptoms
Psychiatric comorbidity (48%)
No prior ECT (32%)
Not meeting minimum severity requirements (21%)

78%

55%

64%
58%, 56%

Not available
Not available

96%

Note. The Filkowski et al. (2015) study was unique in studying deep brain stimulation. The results from this study may not generalize to studies of other treatment types.
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Table 2
Percentage of potential study participants excluded from studies based on speciﬁc exclusion criteria by study.
First Author (Year)

Licht (1997)

Talamo (2008)

Zarin (2005)

Sachs (2012)

Hoertel (2013)

Bowden (1995)

Filkowski (2015)

Overall exclusion rate
Comorbid substance use
Suicide risk/recent suicide attempts
Comorbid medical condition
Age (< 18 or > 65)
Psychotic features
Psychiatric comorbidity
Anxiety disorder
Failure to meet diagnostic criteria/severity requirements
Violent Acts
CNS/neuromuscular disorder
Pregnancy/lactation
Failure to meet diagnostic criteria based on computerized
assessment
Improvement in symptoms from screening to baseline
No Prior ECT
Contraindication
“Safety reasons” (e.g., comorbid substance use, pregnancy,
medical conditions)
“Methodological reasons”
“Non-Compliance”

84%
–
–
–
–
–
–
–
–
–
–
–
–

78%
52%
38%
–
–
–
–
19%
–
23%
–
–
–

55%
39%

58%, 56%
36%, 36%
24%, 21%
20%, 19%
–
6%, 5%
–
–
–
–
–
7%
–

–
–
–
–
–
–
–
–
32%
–
–
–
–

96%
–
2%
17%
2%

–
–
6%
–
–

64%
–
–
–
–
–
–
–
60%
–
–
–
15%

–
–
–
4%

–
–
–
–

–
–
–
–

19%
–
–
–

–
–
–
–

–
–
–
–

–
32%
12%
–

39%
32%

–
–

–
–

–
–

–
–

–
–

–
–

22%
–
–
–

48%
21%
–
–
–
–

Note. — indicates that this ﬁgure was not reported within the corresponding article. Hoertel et al. (2013) results presented for bipolar depression, bipolar mania. Zimmerman et al. (2016)
omitted as this level of data was not reported.

clinical trial participants and 577 prospective participants screened for
another clinical pharmacotherapy trial for acute mania. The authors
estimated that more than 10 patients with bipolar disorder would have
to be screened to enroll 1 patient in an RCT. Comparison between individuals who were included in clinical trials and those who were
drawn from epidemiological samples showed similarities across baseline characteristics.
Zimmerman and colleagues [18] recently identiﬁed 6 inclusion/
exclusion criteria that were used in the majority of a sample of 22 bipolar disorder treatment eﬃcacy trials: minimum severity of depressive
symptoms, suicidal ideation, alcohol/drug use disorder diagnosis, comorbid Axis I disorder, length of current depression episode, and current manic symptoms. Similar to treatment studies of major depressive
disorder, bipolar treatment studies frequently excluded patients based
on comorbid psychiatric and substance use disorders and insuﬃcient
severity of depressive symptoms.
Filkowski and colleagues [19] assessed exclusion within a RCT of
deep brain stimulation. This study is unique in the literature because of
its focus on deep brain stimulation treatment as well as its sample
consisting of bipolar patients who were treatment-refractory to pharmacological and psychological treatments. Potential participants were
recruited via physician, self, or family referral and underwent phone
screenings prior to determination for inclusion/exclusion. Most potential participants with bipolar disorder were excluded for comorbid
psychiatric diagnoses (48%) and lack of prior electroconvulsive therapy
(ECT; 32%), followed by not meeting minimum symptom severity criteria (21%). This study also reported the highest overall exclusion rate
of 96%, leaving only 7 eligible patients out of their initial pool of 163
potential participants. Due to the nature of this treatment, recruitment
was likely more diﬃcult and exclusion eﬀorts were likely more rigorous
than for drug trials. For these reasons, the results of this study may not
generalize to studies of other treatment types.

About two-thirds (60%) of the individuals who were excluded based on
computerized assessment did not meet the key protocol-speciﬁed eligibility requirements related to diagnosis and symptom severity at both
screening and baseline. Approximately 19% of the potential sample
exhibited improvements in their bipolar symptoms during the elapsed
time between screening and baseline interview, which made them ineligible. All the participants identiﬁed as ineligible based on the computerized assessment results were also deemed ineligible by clinical
raters. Conversely, only 64% of individuals who were considered ineligible based on clinical raters would have also been deemed ineligible
by the computerized assessment, suggesting that clinical raters apply
exclusion criteria more stringently than computerized programs designed for the same purpose. Regarding treatment response, there were
no statistically signiﬁcant diﬀerences between treatment conditions and
placebo for any group, although the authors reported an overall trend
of greater response to treatment among individuals who would have
been included versus those excluded. These results should be interpreted with caution, however, given that the lack of signiﬁcance may be
due to either limited eﬀect size or low power.
Hoertel and colleagues [16] identiﬁed exclusion criteria used by at
least 10% of a total sample of 32 randomized controlled trials (RCTs)
for bipolar depression and 55 for acute bipolar mania. The median
number of exclusion criteria was 7, and the researchers had data
available to evaluate 6: comorbid substance use disorder, major medical conditions, psychotic features, suicidal risk, pregnancy or lactation,
and current use of any psychotropic medication. The operationalized
criteria were applied to a sample of community-dwelling individuals
with bipolar depression (N = 785) and bipolar mania (N = 724) drawn
from 2001 to 2002 National Epidemiologic Survey on Alcohol and
Related Conditions data. Of note, these diagnoses were made based on a
fully structured diagnostic interview. Comorbid substance use disorder
(36% for bipolar depression; 36% for bipolar mania), suicide risk (24%
for bipolar depression; 21% for bipolar mania), and a major medical
condition (20% for bipolar depression; 19% for bipolar mania) were the
criteria most likely to exclude individuals from enrolling in a treatment
research study. The majority (58%) of individuals with bipolar depression and 56% of individuals with bipolar mania would have been
excluded from the study based on at least one exclusion criterion. The
expected exclusion rate was even higher (64%) within the subsample of
276 individuals seeking bipolar depression treatment.
Bowden et al. [17] compared descriptive statistics between 179

4. Discussion
The current review of exclusion criteria in clinical trials for bipolar
disorder treatment found total exclusion rates that ranged from 55% to
96% of potential participants. The 55% rate calculated by Zarin and
colleagues is likely an understatement given that 7 was the median
number of exclusion criteria employed used across studies and Zarin
et al. only evaluated 3 criteria. Hoertel et al. [17] also found exclusion
132
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study designs. Further, the monitoring for suicide risk that is employed
within research studies is often more comprehensive than what is traditionally provided in real-world clinical settings, suggesting that including patients at suicidal risk in clinical trials may actually be more
ethical than excluding them.
Exclusion on the basis of medical comorbidities also aﬀects external
validity because of their prevalence among bipolar patients [29,30].
One study estimated 32% of adults with bipolar I disorder have one or
more general medical condition [31]. Other estimates range for 15% for
thyroid disease to 46% for neurological conditions [24]. Thus, signiﬁcant and representative portions of the bipolar patient population
will be excluded from treatment research.
Several of the identiﬁed study ﬁndings suggest that not meeting
suﬃcient diagnostic or severity criteria is a particular issue within bipolar disorder treatment research [15,17,19]. Filkowski, Mayberg, and
Holtzheimer explain that ﬂuctuations in mood states, which are inherent in bipolar disorder, cause the minimum duration of current
episode criterion to be diﬃcult for potential participants to meet,
especially across various time points (i.e., screening, baseline interview). Some research has demonstrated that baseline bipolar disorder
severity is positively associated with number of psychiatric comorbidities, which is one of the most common exclusion criteria [32]. As such,
studies may be employing exclusion criteria (i.e., minimum severity
level, no comorbidity) that conﬂict with one another. Clinical researchers may want to re-evaluate such severity criteria in order to
ensure that they are not inadvertently excluding patients based on the
very characteristics of the disorder that they are attempting to treat.
Our review also found that the populations from which potential
participants are recruited also inﬂuence exclusion rates. Studies recruiting from inpatient hospitalizations had exclusion rates around 80%
whereas samples recruited primarily from outpatient or community
settings ranged from 55 to 65%. As expected, comorbidities and suicidality rates were found to be much higher among inpatient/hospitalized samples than community-dwelling and nationally representative
samples. For instance, comorbid substance use was found in 36% of
Hoertel's potential pool of community-dwelling individuals, whereas
Talamo, Baldessarini, and Centorrino's sample of inpatients included
52% with comorbid substance use. Thus, limits to generalizability due
to exclusion criteria are particularly relevant among studies that focus
on treatments that are administered to inpatient and/or populations of
hospitalized bipolar patients.

relatively lower exclusion rates at 58% and 56% of individuals with
bipolar disorder in the community who may not have been receiving
treatment at the time, but the rate was higher (64%) among those individuals who were currently seeking treatment and therefore better
represent the typical sampling pool in a clinical trial. At the other extreme of the observed range, Filkowski and colleagues' reported exclusion rate (96%) may be attributed to their exclusion criterion of not
receiving “adequate electroconvulsive therapy in the past,” which excluded the second largest proportion of their sample and related to a
unique pre-requisite of their speciﬁc treatment modality of interest
(deep brain stimulation). The remaining studies reported a range of
exclusion between 64% and 84% of potential participants with bipolar
disorder. To avoid false precision, we would characterize this as an
average exclusion ratio in the ﬁeld of about 3 of every 4 bipolar disorder patients being ineligible for treatment research. This ﬁgure is
similar to that found for other psychiatric disorders [5].
Exclusion criteria in bipolar treatment trials are sometimes necessary and useful, but can also make recruitment more diﬃcult and restrict the generalizability of study ﬁndings. Including more representative bipolar patients in research samples could reduce
recruitment barriers and broaden applicability of studying ﬁndings
across bipolar patient populations. Although the studies in the current
review did not provide rationales for their choices regarding exclusion
criteria, other than use in previous clinical trials, explicit justiﬁcation
for criteria are critical to assessing the need for and impact of each
criterion. Understanding the implications of exclusion in bipolar
treatment trials is particularly pertinent given the complexities of bipolar disorder symptoms and the fact that bipolar patients were traditionally excluded from antidepressant trials due to researchers' fears
that treatment might induce a manic episode [20–22]. Even when a
study's exclusion criteria are necessary for ethical reasons, it remains
important to understand how these criteria may inﬂuence study implications and generalizability.
Remarkably, although exclusion criteria are often applied in the
hopes that they will reduce heterogeneity in treatment response, we
found no evidence that they have this eﬀect in bipolar disorder treatment research. Indeed, both studies reviewed found that excluded and
included patients did not signiﬁcantly diﬀer in their outcomes, suggesting that criteria may not have the beneﬁt that putatively trades oﬀ
their downsides (e.g., increased time and resources needed to recruit a
sample, poorer generalizability). Nevertheless, further research in this
area with reported eﬀect sizes are necessary to verify the results from
these two studies.
The four criteria that accounted for the greatest proportion of exclusion across studies were comorbid substance use disorder, suicide
risk, major medical disorders, and minimum symptom severity.
Excluding bipolar patients on these bases has important implications for
generalizability. To take the example of substance use disorder, very
high comorbidity rates have been found among clinical samples of bipolar I (61%) and II patients (48%) [23,24]. Researchers may avoid
including patients with this comorbidity, particularly given evidence
that suggests comorbid substance use disorders are inversely associated
with medication treatment compliance [25] and substance use disorder
is related to poorer treatment response among bipolar patients [26],
[27]. However, explicit statements based on CONSORT guidelines that
clarify the intention and rationale for all exclusion criteria, including
comorbid substance use disorder, should be encouraged, as should
statements in discussion sections that remind readers of the limits on
generalization produced by any exclusion criteria employed [28].
Exclusion for suicidal risk also has a signiﬁcant impact on external
validity. Suicidality is over 20 times higher among patients with bipolar
disorder compared to the general population [3]. Although treatment
research may exclude suicidal patients out of fear of possible increases
in suicidal risk as a result of treatment administration, suicidal risk is
present across patients and treatment studies regardless of who is excluded, warranting appropriate supervision and safeguards within all

4.1. Limitations
Unpublished reports, reports that used alternative terminology, and
reports that were not referenced in PubMed may have been overlooked
by the CREAM projects review method. In addition, lack of reporting on
recruitment strategies and/or use of informal selection criteria in many
of the studies reviewed limited our ability to identify potential other
exclusion criteria and/or biases related to self-selection that may impact the samples that were examined.
4.2. Future directions
The current review sought to inform future decisions about exclusion criteria in studies of treatment for bipolar disorder. In a typical
bipolar disorder treatment study, about 3 in 4 people with the disorder
will be excluded from participation. This raises justiﬁable concern
among clinicians about whether the ﬁndings of research can be safely
and conﬁdently applied in front-line clinical practice. The revised
CONSORT statement requires reporting of exclusion criteria, which
should increase the likelihood that readers will be able to understand
the population to which the results apply. In addition, medical research
often fails to provide explicit rationales for the use of each exclusion
criterion [33]. We suggest that researchers make their rationale for
exclusion criteria explicit. Speciﬁc to studies of bipolar treatments, we
133
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recommend that future studies make a concerted eﬀort to assess and
report the current phase of illness (e.g., mania, hypomania, depression)
among their bipolar patients at the time of recruitment and treatment
administration. Such data provide critical information about the timing
and context for the eﬃcacy of bipolar disorder treatments. We also
encourage researchers designing clinical trials to recruit large, inclusive
bipolar samples from the general population, in order to stratify samples based on common exclusion factors to examine these factors as
potential moderators of treatment eﬀects and identify subgroups for
whom treatments are particularly eﬀective or ineﬀective. We hope that
this review will open a conversation about whether relaxing exclusion
criteria in clinical research on bipolar disorder treatment could increase
the generalizability and clinical relevance of ﬁndings, particularly for
the most vulnerable patients in the health care system.
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